Basic and clinical studies of faropenem in pediatric infection

Ryochi Fujii, Toshiaki Abe, Takeshi Tajima, Itaru Terashima, Hidenori Meguro, Hajime Sato, Kenji Niino, Hiroyuki Suzuki, Yoshikiyo Toyonaga, Hironori Nakamura, Keisuke Sunakawa, Takao Yokota, Hironobu Akita, Satoshi Iwata, Yoshitake Satoh, Tatsuo Kato, Naoichi Iwai, Haruhi Nakamura, Mitsunobu Miyazu, Keiko ItohKuniyoshi Kuno, Hitoshi Kamiya, Kenji Kitamura, Minoru Sakurai, Takashi Nakano, Haruki Mikawa, Masaru Kubota, Hidekazu Nakato, Setsuko Ito, Toru Momoi, Akira Yoshida, Tadafumi Nishimura, Kumiko Sugita, Shigeyuki Aoki, Michio Takagi, Yohnosuke Kobayashi, Minoru Kino, Hirohiko Higashino, Yutaka Kobayashi, Tsunekazu Haruta, Seikyo Furukawa, Takashige Okada, Takashi Okamoto, Takanori Sekiguchi, Yasuhiro Kuroda, Suguru Matsuoka, Takanobu Kurashige, Hiroshi Wakiguchi, Fumihiko Hamada, Taisuke Okada, Akihisa Nagao, Seiji Watanabe, Hiroshi Matsuda, Kaichi Kida, Masatoshi Hayashi, Takashi Motohiro, Shoichi Handa, Shuji Yamada, Shin Ichiro Oki, Yoichiro Yoshinaga, Keiko Oda, Yasutaka Sakata, Hirohisa Kato, Fumio Yamashita, Shoichi Imai, Hirokazu Sasaki, Jun Monta, Masafumi Aramaki, Yoshinori Matsuguma, Tomoshige Hirata, Nobuo Tanaka, Hisaaki Araki, Kiyotaka Nagayama, Masao Hayashi, Chikai Yasuoka, Eiichiro Ono, Ken Yuge, Nobuo Hashimoto, Keiko Sueyoshi, Kaoru Kubota, Akira Kawakami, Emi Higuchi, Toru Nishiyama, Kaoru Tominaga, Naoki Kuda, Tatsuhiko Koga, Tamotsu Fujimoto, Hiroshi Hayakawa, Toru Sugimura

Research output: Contribution to journalArticle

Abstract

Newly developed faropenem (FRPM) was evaluated clinically and pharmacokinetically in pediatrics as follows. 1. Efficacy The clinical efficacy was determined in 494 cases. The efficacy rate was 91.9% (271/295) in 295 patients from whom the above causal agents were isolated and 93.0% (185/199) in 199 patients without isolation of the agent. The bacteriological eradication rate was 82.5% (250/303 strains). The MICs of FRPM for penicillin resistant Streptococcus pneumoniae (PRSP) were ≤0.025 to 0.2 μg/ml. In all 10 cases, the clinical efficacy was more than good. The bacteriological eradication rate was 6 out of 8. The clinical efgcacy rate for cases which were non-responsive to previous chemotherapy was 89.3% (50/56). 2. Safety Side effects were observed in 6.6% (36/548) of the evaluated cases for safety. These were diarrhea, loose stool, gluteal candidiasis, urticaria and rash. There were abnormal laboratory findings in 37 cases including elevation of eosinophile, GPT, GOT, γ-GTP. None of the side effects or abnormal laboratory findings were serious. 3. Palatability of the drug The palatability of the drug was quite good. It was evaluated as more than moderate by 99.3% (555/559) of the patients. From the above results FRPM is considered to be quite useful in pediatric infections including PRSP infections.

Original languageEnglish
Pages (from-to)888-890
Number of pages3
JournalJapanese Journal of Chemotherapy
Volume45
Issue number10
Publication statusPublished - 1997
Externally publishedYes

Fingerprint

Pediatrics
Penicillins
Infection
Patient Isolation
Safety
Pneumococcal Infections
Candidiasis
Urticaria
Guanosine Triphosphate
Streptococcus pneumoniae
Exanthema
Eosinophils
Pharmaceutical Preparations
Diarrhea
Drug Therapy
Clinical Studies
fropenem

ASJC Scopus subject areas

  • Pharmacology

Cite this

Fujii, R., Abe, T., Tajima, T., Terashima, I., Meguro, H., Sato, H., ... Sugimura, T. (1997). Basic and clinical studies of faropenem in pediatric infection. Japanese Journal of Chemotherapy, 45(10), 888-890.

Basic and clinical studies of faropenem in pediatric infection. / Fujii, Ryochi; Abe, Toshiaki; Tajima, Takeshi; Terashima, Itaru; Meguro, Hidenori; Sato, Hajime; Niino, Kenji; Suzuki, Hiroyuki; Toyonaga, Yoshikiyo; Nakamura, Hironori; Sunakawa, Keisuke; Yokota, Takao; Akita, Hironobu; Iwata, Satoshi; Satoh, Yoshitake; Kato, Tatsuo; Iwai, Naoichi; Nakamura, Haruhi; Miyazu, Mitsunobu; Itoh, Keiko; Kuno, Kuniyoshi; Kamiya, Hitoshi; Kitamura, Kenji; Sakurai, Minoru; Nakano, Takashi; Mikawa, Haruki; Kubota, Masaru; Nakato, Hidekazu; Ito, Setsuko; Momoi, Toru; Yoshida, Akira; Nishimura, Tadafumi; Sugita, Kumiko; Aoki, Shigeyuki; Takagi, Michio; Kobayashi, Yohnosuke; Kino, Minoru; Higashino, Hirohiko; Kobayashi, Yutaka; Haruta, Tsunekazu; Furukawa, Seikyo; Okada, Takashige; Okamoto, Takashi; Sekiguchi, Takanori; Kuroda, Yasuhiro; Matsuoka, Suguru; Kurashige, Takanobu; Wakiguchi, Hiroshi; Hamada, Fumihiko; Okada, Taisuke; Nagao, Akihisa; Watanabe, Seiji; Matsuda, Hiroshi; Kida, Kaichi; Hayashi, Masatoshi; Motohiro, Takashi; Handa, Shoichi; Yamada, Shuji; Oki, Shin Ichiro; Yoshinaga, Yoichiro; Oda, Keiko; Sakata, Yasutaka; Kato, Hirohisa; Yamashita, Fumio; Imai, Shoichi; Sasaki, Hirokazu; Monta, Jun; Aramaki, Masafumi; Matsuguma, Yoshinori; Hirata, Tomoshige; Tanaka, Nobuo; Araki, Hisaaki; Nagayama, Kiyotaka; Hayashi, Masao; Yasuoka, Chikai; Ono, Eiichiro; Yuge, Ken; Hashimoto, Nobuo; Sueyoshi, Keiko; Kubota, Kaoru; Kawakami, Akira; Higuchi, Emi; Nishiyama, Toru; Tominaga, Kaoru; Kuda, Naoki; Koga, Tatsuhiko; Fujimoto, Tamotsu; Hayakawa, Hiroshi; Sugimura, Toru.

In: Japanese Journal of Chemotherapy, Vol. 45, No. 10, 1997, p. 888-890.

Research output: Contribution to journalArticle

Fujii, R, Abe, T, Tajima, T, Terashima, I, Meguro, H, Sato, H, Niino, K, Suzuki, H, Toyonaga, Y, Nakamura, H, Sunakawa, K, Yokota, T, Akita, H, Iwata, S, Satoh, Y, Kato, T, Iwai, N, Nakamura, H, Miyazu, M, Itoh, K, Kuno, K, Kamiya, H, Kitamura, K, Sakurai, M, Nakano, T, Mikawa, H, Kubota, M, Nakato, H, Ito, S, Momoi, T, Yoshida, A, Nishimura, T, Sugita, K, Aoki, S, Takagi, M, Kobayashi, Y, Kino, M, Higashino, H, Kobayashi, Y, Haruta, T, Furukawa, S, Okada, T, Okamoto, T, Sekiguchi, T, Kuroda, Y, Matsuoka, S, Kurashige, T, Wakiguchi, H, Hamada, F, Okada, T, Nagao, A, Watanabe, S, Matsuda, H, Kida, K, Hayashi, M, Motohiro, T, Handa, S, Yamada, S, Oki, SI, Yoshinaga, Y, Oda, K, Sakata, Y, Kato, H, Yamashita, F, Imai, S, Sasaki, H, Monta, J, Aramaki, M, Matsuguma, Y, Hirata, T, Tanaka, N, Araki, H, Nagayama, K, Hayashi, M, Yasuoka, C, Ono, E, Yuge, K, Hashimoto, N, Sueyoshi, K, Kubota, K, Kawakami, A, Higuchi, E, Nishiyama, T, Tominaga, K, Kuda, N, Koga, T, Fujimoto, T, Hayakawa, H & Sugimura, T 1997, 'Basic and clinical studies of faropenem in pediatric infection', Japanese Journal of Chemotherapy, vol. 45, no. 10, pp. 888-890.
Fujii R, Abe T, Tajima T, Terashima I, Meguro H, Sato H et al. Basic and clinical studies of faropenem in pediatric infection. Japanese Journal of Chemotherapy. 1997;45(10):888-890.
Fujii, Ryochi ; Abe, Toshiaki ; Tajima, Takeshi ; Terashima, Itaru ; Meguro, Hidenori ; Sato, Hajime ; Niino, Kenji ; Suzuki, Hiroyuki ; Toyonaga, Yoshikiyo ; Nakamura, Hironori ; Sunakawa, Keisuke ; Yokota, Takao ; Akita, Hironobu ; Iwata, Satoshi ; Satoh, Yoshitake ; Kato, Tatsuo ; Iwai, Naoichi ; Nakamura, Haruhi ; Miyazu, Mitsunobu ; Itoh, Keiko ; Kuno, Kuniyoshi ; Kamiya, Hitoshi ; Kitamura, Kenji ; Sakurai, Minoru ; Nakano, Takashi ; Mikawa, Haruki ; Kubota, Masaru ; Nakato, Hidekazu ; Ito, Setsuko ; Momoi, Toru ; Yoshida, Akira ; Nishimura, Tadafumi ; Sugita, Kumiko ; Aoki, Shigeyuki ; Takagi, Michio ; Kobayashi, Yohnosuke ; Kino, Minoru ; Higashino, Hirohiko ; Kobayashi, Yutaka ; Haruta, Tsunekazu ; Furukawa, Seikyo ; Okada, Takashige ; Okamoto, Takashi ; Sekiguchi, Takanori ; Kuroda, Yasuhiro ; Matsuoka, Suguru ; Kurashige, Takanobu ; Wakiguchi, Hiroshi ; Hamada, Fumihiko ; Okada, Taisuke ; Nagao, Akihisa ; Watanabe, Seiji ; Matsuda, Hiroshi ; Kida, Kaichi ; Hayashi, Masatoshi ; Motohiro, Takashi ; Handa, Shoichi ; Yamada, Shuji ; Oki, Shin Ichiro ; Yoshinaga, Yoichiro ; Oda, Keiko ; Sakata, Yasutaka ; Kato, Hirohisa ; Yamashita, Fumio ; Imai, Shoichi ; Sasaki, Hirokazu ; Monta, Jun ; Aramaki, Masafumi ; Matsuguma, Yoshinori ; Hirata, Tomoshige ; Tanaka, Nobuo ; Araki, Hisaaki ; Nagayama, Kiyotaka ; Hayashi, Masao ; Yasuoka, Chikai ; Ono, Eiichiro ; Yuge, Ken ; Hashimoto, Nobuo ; Sueyoshi, Keiko ; Kubota, Kaoru ; Kawakami, Akira ; Higuchi, Emi ; Nishiyama, Toru ; Tominaga, Kaoru ; Kuda, Naoki ; Koga, Tatsuhiko ; Fujimoto, Tamotsu ; Hayakawa, Hiroshi ; Sugimura, Toru. / Basic and clinical studies of faropenem in pediatric infection. In: Japanese Journal of Chemotherapy. 1997 ; Vol. 45, No. 10. pp. 888-890.
@article{2915d71bb5cc4a0dbba9ee185ceccb8f,
title = "Basic and clinical studies of faropenem in pediatric infection",
abstract = "Newly developed faropenem (FRPM) was evaluated clinically and pharmacokinetically in pediatrics as follows. 1. Efficacy The clinical efficacy was determined in 494 cases. The efficacy rate was 91.9{\%} (271/295) in 295 patients from whom the above causal agents were isolated and 93.0{\%} (185/199) in 199 patients without isolation of the agent. The bacteriological eradication rate was 82.5{\%} (250/303 strains). The MICs of FRPM for penicillin resistant Streptococcus pneumoniae (PRSP) were ≤0.025 to 0.2 μg/ml. In all 10 cases, the clinical efficacy was more than good. The bacteriological eradication rate was 6 out of 8. The clinical efgcacy rate for cases which were non-responsive to previous chemotherapy was 89.3{\%} (50/56). 2. Safety Side effects were observed in 6.6{\%} (36/548) of the evaluated cases for safety. These were diarrhea, loose stool, gluteal candidiasis, urticaria and rash. There were abnormal laboratory findings in 37 cases including elevation of eosinophile, GPT, GOT, γ-GTP. None of the side effects or abnormal laboratory findings were serious. 3. Palatability of the drug The palatability of the drug was quite good. It was evaluated as more than moderate by 99.3{\%} (555/559) of the patients. From the above results FRPM is considered to be quite useful in pediatric infections including PRSP infections.",
author = "Ryochi Fujii and Toshiaki Abe and Takeshi Tajima and Itaru Terashima and Hidenori Meguro and Hajime Sato and Kenji Niino and Hiroyuki Suzuki and Yoshikiyo Toyonaga and Hironori Nakamura and Keisuke Sunakawa and Takao Yokota and Hironobu Akita and Satoshi Iwata and Yoshitake Satoh and Tatsuo Kato and Naoichi Iwai and Haruhi Nakamura and Mitsunobu Miyazu and Keiko Itoh and Kuniyoshi Kuno and Hitoshi Kamiya and Kenji Kitamura and Minoru Sakurai and Takashi Nakano and Haruki Mikawa and Masaru Kubota and Hidekazu Nakato and Setsuko Ito and Toru Momoi and Akira Yoshida and Tadafumi Nishimura and Kumiko Sugita and Shigeyuki Aoki and Michio Takagi and Yohnosuke Kobayashi and Minoru Kino and Hirohiko Higashino and Yutaka Kobayashi and Tsunekazu Haruta and Seikyo Furukawa and Takashige Okada and Takashi Okamoto and Takanori Sekiguchi and Yasuhiro Kuroda and Suguru Matsuoka and Takanobu Kurashige and Hiroshi Wakiguchi and Fumihiko Hamada and Taisuke Okada and Akihisa Nagao and Seiji Watanabe and Hiroshi Matsuda and Kaichi Kida and Masatoshi Hayashi and Takashi Motohiro and Shoichi Handa and Shuji Yamada and Oki, {Shin Ichiro} and Yoichiro Yoshinaga and Keiko Oda and Yasutaka Sakata and Hirohisa Kato and Fumio Yamashita and Shoichi Imai and Hirokazu Sasaki and Jun Monta and Masafumi Aramaki and Yoshinori Matsuguma and Tomoshige Hirata and Nobuo Tanaka and Hisaaki Araki and Kiyotaka Nagayama and Masao Hayashi and Chikai Yasuoka and Eiichiro Ono and Ken Yuge and Nobuo Hashimoto and Keiko Sueyoshi and Kaoru Kubota and Akira Kawakami and Emi Higuchi and Toru Nishiyama and Kaoru Tominaga and Naoki Kuda and Tatsuhiko Koga and Tamotsu Fujimoto and Hiroshi Hayakawa and Toru Sugimura",
year = "1997",
language = "English",
volume = "45",
pages = "888--890",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "10",

}

TY - JOUR

T1 - Basic and clinical studies of faropenem in pediatric infection

AU - Fujii, Ryochi

AU - Abe, Toshiaki

AU - Tajima, Takeshi

AU - Terashima, Itaru

AU - Meguro, Hidenori

AU - Sato, Hajime

AU - Niino, Kenji

AU - Suzuki, Hiroyuki

AU - Toyonaga, Yoshikiyo

AU - Nakamura, Hironori

AU - Sunakawa, Keisuke

AU - Yokota, Takao

AU - Akita, Hironobu

AU - Iwata, Satoshi

AU - Satoh, Yoshitake

AU - Kato, Tatsuo

AU - Iwai, Naoichi

AU - Nakamura, Haruhi

AU - Miyazu, Mitsunobu

AU - Itoh, Keiko

AU - Kuno, Kuniyoshi

AU - Kamiya, Hitoshi

AU - Kitamura, Kenji

AU - Sakurai, Minoru

AU - Nakano, Takashi

AU - Mikawa, Haruki

AU - Kubota, Masaru

AU - Nakato, Hidekazu

AU - Ito, Setsuko

AU - Momoi, Toru

AU - Yoshida, Akira

AU - Nishimura, Tadafumi

AU - Sugita, Kumiko

AU - Aoki, Shigeyuki

AU - Takagi, Michio

AU - Kobayashi, Yohnosuke

AU - Kino, Minoru

AU - Higashino, Hirohiko

AU - Kobayashi, Yutaka

AU - Haruta, Tsunekazu

AU - Furukawa, Seikyo

AU - Okada, Takashige

AU - Okamoto, Takashi

AU - Sekiguchi, Takanori

AU - Kuroda, Yasuhiro

AU - Matsuoka, Suguru

AU - Kurashige, Takanobu

AU - Wakiguchi, Hiroshi

AU - Hamada, Fumihiko

AU - Okada, Taisuke

AU - Nagao, Akihisa

AU - Watanabe, Seiji

AU - Matsuda, Hiroshi

AU - Kida, Kaichi

AU - Hayashi, Masatoshi

AU - Motohiro, Takashi

AU - Handa, Shoichi

AU - Yamada, Shuji

AU - Oki, Shin Ichiro

AU - Yoshinaga, Yoichiro

AU - Oda, Keiko

AU - Sakata, Yasutaka

AU - Kato, Hirohisa

AU - Yamashita, Fumio

AU - Imai, Shoichi

AU - Sasaki, Hirokazu

AU - Monta, Jun

AU - Aramaki, Masafumi

AU - Matsuguma, Yoshinori

AU - Hirata, Tomoshige

AU - Tanaka, Nobuo

AU - Araki, Hisaaki

AU - Nagayama, Kiyotaka

AU - Hayashi, Masao

AU - Yasuoka, Chikai

AU - Ono, Eiichiro

AU - Yuge, Ken

AU - Hashimoto, Nobuo

AU - Sueyoshi, Keiko

AU - Kubota, Kaoru

AU - Kawakami, Akira

AU - Higuchi, Emi

AU - Nishiyama, Toru

AU - Tominaga, Kaoru

AU - Kuda, Naoki

AU - Koga, Tatsuhiko

AU - Fujimoto, Tamotsu

AU - Hayakawa, Hiroshi

AU - Sugimura, Toru

PY - 1997

Y1 - 1997

N2 - Newly developed faropenem (FRPM) was evaluated clinically and pharmacokinetically in pediatrics as follows. 1. Efficacy The clinical efficacy was determined in 494 cases. The efficacy rate was 91.9% (271/295) in 295 patients from whom the above causal agents were isolated and 93.0% (185/199) in 199 patients without isolation of the agent. The bacteriological eradication rate was 82.5% (250/303 strains). The MICs of FRPM for penicillin resistant Streptococcus pneumoniae (PRSP) were ≤0.025 to 0.2 μg/ml. In all 10 cases, the clinical efficacy was more than good. The bacteriological eradication rate was 6 out of 8. The clinical efgcacy rate for cases which were non-responsive to previous chemotherapy was 89.3% (50/56). 2. Safety Side effects were observed in 6.6% (36/548) of the evaluated cases for safety. These were diarrhea, loose stool, gluteal candidiasis, urticaria and rash. There were abnormal laboratory findings in 37 cases including elevation of eosinophile, GPT, GOT, γ-GTP. None of the side effects or abnormal laboratory findings were serious. 3. Palatability of the drug The palatability of the drug was quite good. It was evaluated as more than moderate by 99.3% (555/559) of the patients. From the above results FRPM is considered to be quite useful in pediatric infections including PRSP infections.

AB - Newly developed faropenem (FRPM) was evaluated clinically and pharmacokinetically in pediatrics as follows. 1. Efficacy The clinical efficacy was determined in 494 cases. The efficacy rate was 91.9% (271/295) in 295 patients from whom the above causal agents were isolated and 93.0% (185/199) in 199 patients without isolation of the agent. The bacteriological eradication rate was 82.5% (250/303 strains). The MICs of FRPM for penicillin resistant Streptococcus pneumoniae (PRSP) were ≤0.025 to 0.2 μg/ml. In all 10 cases, the clinical efficacy was more than good. The bacteriological eradication rate was 6 out of 8. The clinical efgcacy rate for cases which were non-responsive to previous chemotherapy was 89.3% (50/56). 2. Safety Side effects were observed in 6.6% (36/548) of the evaluated cases for safety. These were diarrhea, loose stool, gluteal candidiasis, urticaria and rash. There were abnormal laboratory findings in 37 cases including elevation of eosinophile, GPT, GOT, γ-GTP. None of the side effects or abnormal laboratory findings were serious. 3. Palatability of the drug The palatability of the drug was quite good. It was evaluated as more than moderate by 99.3% (555/559) of the patients. From the above results FRPM is considered to be quite useful in pediatric infections including PRSP infections.

UR - http://www.scopus.com/inward/record.url?scp=0030734966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030734966&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030734966

VL - 45

SP - 888

EP - 890

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - 10

ER -